Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application
- PMID: 15638853
- DOI: 10.1111/j.1365-2141.2004.05286.x
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application
Abstract
Thalidomide and immunomodulatory drugs (IMiDs), which _target multiple myeloma (MM) cells and the bone marrow microenvironment, can overcome drug resistance. These agents also have immunomodulatory effects. Specifically, we have reported that thalidomide increased serum interleukin-2 (IL-2) levels and natural killer (NK) cell numbers in the peripheral blood of responding MM patients. In this study, we investigated the mechanisms whereby IMiDs augment NK cell cytotoxicity. NK cytotoxicity and antibody-dependent cell-mediated cytotoxicity (ADCC) of peripheral blood mononuclear cells cultured with IMiDs were examined in the presence or absence of anti-IL-2 antibody, ciclosporin A or depletion of CD56-positive cells. IMiDs-induced signalling pathways, triggering IL-2 transcription in T cells, were also delineated. IMiDs facilitated the nuclear translocation of nuclear factor of activated T cells-2 and activator protein-1 via activation of phosphoinositide-3 kinase signalling, with resultant IL-2 secretion. IMiDs enhanced both NK cell cytotoxicity and ADCC induced by triggering IL-2 production from T cells. These studies defined the mechanisms whereby IMiDs trigger NK cell-mediated tumour-cell lysis, further supporting their therapeutic use in MM.
Similar articles
-
Lenalidomide and thalidomide: mechanisms of action--similarities and differences.Semin Hematol. 2005 Oct;42(4 Suppl 4):S3-8. doi: 10.1053/j.seminhematol.2005.10.001. Semin Hematol. 2005. PMID: 16344099 Review.
-
Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications.Cancer Res. 2005 Dec 15;65(24):11712-20. doi: 10.1158/0008-5472.CAN-05-1657. Cancer Res. 2005. PMID: 16357183
-
Mechanism of norepinephrine-mediated inhibition of human NK cytotoxic functions: inhibition of cytokine secretion, _target binding, and programming for cytotoxicity.Brain Behav Immun. 2002 Jun;16(3):227-46. doi: 10.1006/brbi.2000.0615. Brain Behav Immun. 2002. PMID: 12009684
-
NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.Exp Hematol. 2008 Jan;36(1):69-77. doi: 10.1016/j.exphem.2007.08.012. Epub 2007 Oct 23. Exp Hematol. 2008. PMID: 17959301
-
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma.Leukemia. 2010 Jan;24(1):22-32. doi: 10.1038/leu.2009.236. Epub 2009 Nov 12. Leukemia. 2010. PMID: 19907437 Free PMC article. Review.
Cited by
-
Immune System Alterations in Multiple Myeloma: Molecular Mechanisms and Therapeutic Strategies to Reverse Immunosuppression.Cancers (Basel). 2021 Mar 17;13(6):1353. doi: 10.3390/cancers13061353. Cancers (Basel). 2021. PMID: 33802806 Free PMC article. Review.
-
A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma.Blood. 2012 Nov 22;120(22):4324-33. doi: 10.1182/blood-2012-06-438028. Epub 2012 Oct 1. Blood. 2012. PMID: 23033266 Free PMC article. Clinical Trial.
-
Autologous Stem Cell Transplantation for Myeloma: Cytoreduction or an Immunotherapy?Front Immunol. 2021 Mar 12;12:651288. doi: 10.3389/fimmu.2021.651288. eCollection 2021. Front Immunol. 2021. PMID: 33777050 Free PMC article.
-
Epigenetic induction of adaptive immune response in multiple myeloma: sequential azacitidine and lenalidomide generate cancer testis antigen-specific cellular immunity.Br J Haematol. 2012 Sep;158(6):700-11. doi: 10.1111/j.1365-2141.2012.09225.x. Epub 2012 Jul 23. Br J Haematol. 2012. PMID: 22816680 Free PMC article. Clinical Trial.
-
IKAROS and AIOLOS directly regulate AP-1 transcriptional complexes and are essential for NK cell development.Nat Immunol. 2024 Feb;25(2):240-255. doi: 10.1038/s41590-023-01718-4. Epub 2024 Jan 5. Nat Immunol. 2024. PMID: 38182668
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials